Clinical Study

Racial/Ethnic Patterns in Prostate Cancer Outcomes in an Active Surveillance Cohort

Table 4

Multivariable Cox proportional hazards model predicting overall survival in a cohort of subjects with prostate cancer (CaP) followed on active surveillance (AS) for primary treatment, stratified by secondary treatment type.

Secondary treatment type characteristicNone (AS only)RP3EBRT-Br4HT5
HOR1 (95% CI2)P valueHOR (95% CI)P valueHOR (95% CI)P valueHOR (95% CI)P value

Age at diagnosis, years0.17370.15320.37430.4236
 <60ReferentReferentReferentReferent
 60–60.92.43 (0.84–6.97)0.09831.65 (0.35–7.60)0.51961.35 (0.45–4.02)0.58361.84 (0.40–8.27)0.4264
 ≥702.700 (0.95–7.64)0.06164.41 (0.85–22.7)0.07621.84 (0.62–5.42)0.26631.32 (0.30–5.74)0.7108
Race
 WhiteReferentReferentReferentReferent
 Black1.24 (0.74–2.07)0.41200.46 (0.09–2.32)0.35221.14 (0.64–2.03)0.64781.17 (0.60–2.29)0.6282
Comorbidities0.32180.44640.00610.5145
 0ReferentReferentReferentReferent
 11.15 (0.66–1.99)0.60592.42 (0.65–8.99)0.18650.58 (0.27–1.23)0.15821.06 (0.53–2.12)0.8657
 21.60 (0.85–3.02)0.14250.97 (0.19–4.84)0.97310.48 (0.21–1.06)0.07241.22 (0.60–2.46)0.5730
 ≥31.53 (0.86–2.71)0.14312.05 (0.33–12.6)0.43611.70 (0.82–3.53)0.15180.71 (0.34–1.50)0.3800
D’Amico et al. risk strata<0.00010.03530.00070.0787
 LowReferentReferentReferentReferent
 Intermediate1.47 (0.88–2.45)0.13711.78 (0.44–7.12)0.41242.16 (0.99–4.71)0.05281.75 (0.87–3.51)0.1112
 High3.52 (2.18–5.69)<0.00015.64 (1.48–21.4)0.01104.20 (1.98–8.90)0.00022.03 (1.09–3.78)0.0257
Dx6 to secondary treatment, months1.00 (0.97–1.03)0.86350.98 (0.97–1.00)0.04240.98 (0.975–0.99)0.0010

1HOR: hazard Odds Ratio.
2CI: confidence Interval.
3RP: radical prostatectomy.
4 EBRT-BR: external beam radiation therapy and Brachytherapy, combined.
5HT: hormone therapy.
6 Dx: diagnosis of CaP.